JP2017505313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505313A5 JP2017505313A5 JP2016548269A JP2016548269A JP2017505313A5 JP 2017505313 A5 JP2017505313 A5 JP 2017505313A5 JP 2016548269 A JP2016548269 A JP 2016548269A JP 2016548269 A JP2016548269 A JP 2016548269A JP 2017505313 A5 JP2017505313 A5 JP 2017505313A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- fluorine
- optionally substituted
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052731 fluorine Inorganic materials 0.000 claims description 59
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 58
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 58
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 56
- 239000011737 fluorine Substances 0.000 claims description 56
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 23
- 229910052801 chlorine Inorganic materials 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 14
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 6
- -1 or C 1 -C 6 alkyl Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- 229910014033 C-OH Inorganic materials 0.000 claims description 2
- 229910014570 C—OH Inorganic materials 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930031P | 2014-01-22 | 2014-01-22 | |
| US61/930,031 | 2014-01-22 | ||
| PCT/EP2015/000105 WO2015110262A1 (en) | 2014-01-22 | 2015-01-21 | Novel cyp-eicosanoid derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505313A JP2017505313A (ja) | 2017-02-16 |
| JP2017505313A5 true JP2017505313A5 (enExample) | 2019-08-29 |
| JP6577951B2 JP6577951B2 (ja) | 2019-09-18 |
Family
ID=52446335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548269A Active JP6577951B2 (ja) | 2014-01-22 | 2015-01-21 | 新規ｃｙｐ−エイコサノイド誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11130772B2 (enExample) |
| EP (1) | EP3097076B1 (enExample) |
| JP (1) | JP6577951B2 (enExample) |
| KR (1) | KR102392893B1 (enExample) |
| CN (2) | CN110950786A (enExample) |
| AU (1) | AU2015208416B2 (enExample) |
| BR (1) | BR112016016139B1 (enExample) |
| CA (1) | CA2934964C (enExample) |
| CY (1) | CY1122591T1 (enExample) |
| DK (1) | DK3097076T3 (enExample) |
| ES (1) | ES2738701T3 (enExample) |
| HR (1) | HRP20191315T1 (enExample) |
| HU (1) | HUE044703T2 (enExample) |
| LT (1) | LT3097076T (enExample) |
| MX (1) | MX368689B (enExample) |
| PL (1) | PL3097076T3 (enExample) |
| PT (1) | PT3097076T (enExample) |
| RS (1) | RS59218B1 (enExample) |
| RU (1) | RU2730512C2 (enExample) |
| SI (1) | SI3097076T1 (enExample) |
| SM (1) | SMT201900438T1 (enExample) |
| WO (1) | WO2015110262A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11096910B2 (en) * | 2015-07-22 | 2021-08-24 | Max Delbruck-Centrum Fur Molekulare Medizin | Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease |
| WO2017168007A1 (en) * | 2016-04-01 | 2017-10-05 | Omeicos Therapeutics Gmbh | Analogs of cyp-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation |
| SI3435993T1 (sl) | 2016-04-01 | 2025-03-31 | Omeicos Therapeutics Gmbh | Analog cyp-eikozanoidov za uporabo pri zdravljenju ali preprečevanju motnje, povezane z neovaskularizacijo in/ali vnetjem |
| JP7080826B2 (ja) * | 2016-05-16 | 2022-06-06 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
| JP2024542612A (ja) | 2021-11-26 | 2024-11-15 | オメイコス セラピューティクス ジーエムビーエイチ | Ｇｄｆ１５血漿濃度の上昇に関連する疾患の治療および予防のための合成エイコサノイド類似体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753702A (en) | 1996-05-22 | 1998-05-19 | University Of Vermont | Arachidonic acid metabolite, 16-hete |
| US6395781B1 (en) | 1998-02-26 | 2002-05-28 | Mcw Research Foundation | 20-HETE antagonists and agonists |
| US20020151734A1 (en) | 2001-01-02 | 2002-10-17 | Schwartzman Michal Laniado | 12-HETrE analogs and methods of use thereof |
| WO2004080389A2 (en) | 2003-03-07 | 2004-09-23 | Taisho Pharmaceutical Co., Ltd. | Hydroxyeicosadienamide compounds |
| US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
| US20080306155A1 (en) | 2004-09-16 | 2008-12-11 | Roman Richard J | Method for treating renal disease |
| US20080095711A1 (en) | 2006-08-31 | 2008-04-24 | Falck John R | Modulators of Pulmonary Hypertension |
| US7550617B2 (en) | 2006-10-02 | 2009-06-23 | Medical College Of Georgia Research Institute | Compositions and methods for the treatment of renal and cardiovascular disease |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| EP2208720A1 (en) * | 2009-01-13 | 2010-07-21 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Novel eicosanoid derivatives |
| WO2011066414A1 (en) | 2009-11-25 | 2011-06-03 | Cytometix, Inc. | Arachidonic acid analogs and methods for analgesic treatment using same |
| EP2694470B1 (en) * | 2011-04-06 | 2016-06-01 | The Medical College of Wisconsin, Inc. | Epoxyeicosatrienoic acid analogs and methods of making and using the same |
-
2015
- 2015-01-21 CN CN201911170917.5A patent/CN110950786A/zh active Pending
- 2015-01-21 SI SI201530839T patent/SI3097076T1/sl unknown
- 2015-01-21 LT LTEP15702370.6T patent/LT3097076T/lt unknown
- 2015-01-21 HU HUE15702370 patent/HUE044703T2/hu unknown
- 2015-01-21 SM SM20190438T patent/SMT201900438T1/it unknown
- 2015-01-21 JP JP2016548269A patent/JP6577951B2/ja active Active
- 2015-01-21 RU RU2016133336A patent/RU2730512C2/ru active
- 2015-01-21 AU AU2015208416A patent/AU2015208416B2/en active Active
- 2015-01-21 BR BR112016016139-4A patent/BR112016016139B1/pt active IP Right Grant
- 2015-01-21 CA CA2934964A patent/CA2934964C/en active Active
- 2015-01-21 PL PL15702370T patent/PL3097076T3/pl unknown
- 2015-01-21 KR KR1020167022894A patent/KR102392893B1/ko active Active
- 2015-01-21 RS RSP20190960 patent/RS59218B1/sr unknown
- 2015-01-21 HR HRP20191315TT patent/HRP20191315T1/hr unknown
- 2015-01-21 WO PCT/EP2015/000105 patent/WO2015110262A1/en not_active Ceased
- 2015-01-21 ES ES15702370T patent/ES2738701T3/es active Active
- 2015-01-21 US US15/113,139 patent/US11130772B2/en active Active
- 2015-01-21 DK DK15702370.6T patent/DK3097076T3/da active
- 2015-01-21 EP EP15702370.6A patent/EP3097076B1/en active Active
- 2015-01-21 CN CN201580005451.7A patent/CN106061942B/zh active Active
- 2015-01-21 MX MX2016009507A patent/MX368689B/es active IP Right Grant
- 2015-01-21 PT PT15702370T patent/PT3097076T/pt unknown
-
2019
- 2019-08-07 CY CY20191100843T patent/CY1122591T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5536229B2 (ja) | Ｈｃｖ併用療法 | |
| RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
| JP2017505313A5 (enExample) | ||
| ES2414472T3 (es) | Composición farmacéutica de liberación sostenida de acetato de octreotide | |
| ES2652595T3 (es) | Lactonas de sesquiterpeno tricíclico para el uso en el tratamiento de la obesidad y enfermedades relacionadas y condiciones tratables no terapéuticas | |
| JP6462045B2 (ja) | スルフォラファンの単離及び精製 | |
| TWI710555B (zh) | 新穎水溶性前藥 | |
| EA026100B1 (ru) | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение | |
| CN103702973B (zh) | 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 | |
| JP2019515908A5 (enExample) | ||
| RU2018101439A (ru) | Метаболически устойчивые аналоги cyp-эйкозаноидов для лечения кардиологических заболеваний | |
| RU2015118581A (ru) | Лиофилизированные препараты мелфалана флуфенамида | |
| ES2773674T3 (es) | Sofosbuvir en forma cristalina y procedimiento para su preparación | |
| CA2602514A1 (en) | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage | |
| EP3922251B1 (en) | Cancer immunotheraphy adjuvant | |
| JP2020079261A (ja) | （１Ｅ，４Ｅ）−２−アミノ−Ｎ，Ｎ−ジプロピル−８−（４−（ピロリジン−１−カルボニル）フェニル）−３Ｈ−ベンゾ［ｂ］アゼピン−４−カルボキサミドを含む固体形態、その組成物、およびその使用 | |
| RU2016133336A (ru) | Новые производные CYP-эйкозаноидов | |
| JP2009526834A5 (enExample) | ||
| CA2552855A1 (en) | Azabicyclooctan-3-one derivatives and use thereof | |
| CN109956975A (zh) | 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用 | |
| CA3062883C (en) | Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same | |
| JP2021501202A5 (enExample) | ||
| ES2671730T3 (es) | Terapia de combinación para el cáncer de ovario | |
| ES2641143T3 (es) | Una composición farmacéutica que comprende palmitoiletanolamida y citidina-difosfocolina | |
| JP2020511437A5 (enExample) |